Transenterix (NASDAQ: TRXC) and C.R. Bard (NYSE:BCR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Transenterix and C.R. Bard’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Transenterix -928.85% -49.16% -33.51%
C.R. Bard 14.75% 48.28% 16.23%

Valuation and Earnings

This table compares Transenterix and C.R. Bard’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Transenterix $5.05 million 87.06 -$47.82 million N/A N/A
C.R. Bard $3.83 billion 6.21 $1.18 billion $7.59 43.09

C.R. Bard has higher revenue and earnings than Transenterix.

Dividends

C.R. Bard pays an annual dividend of $1.04 per share and has a dividend yield of 0.3%. Transenterix does not pay a dividend. C.R. Bard pays out 13.7% of its earnings in the form of a dividend. C.R. Bard has increased its dividend for 45 consecutive years.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Transenterix and C.R. Bard, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Transenterix 0 1 2 0 2.67
C.R. Bard 0 7 0 0 2.00

Transenterix currently has a consensus target price of $3.23, indicating a potential upside of 9.23%. C.R. Bard has a consensus target price of $282.29, indicating a potential downside of 13.69%. Given Transenterix’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Transenterix is more favorable than C.R. Bard.

Institutional and Insider Ownership

79.3% of C.R. Bard shares are owned by institutional investors. 0.8% of C.R. Bard shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

C.R. Bard beats Transenterix on 9 of the 14 factors compared between the two stocks.

Transenterix Company Profile

TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.

C.R. Bard Company Profile

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.